For the past 15 years, Gerald W. Smetana, MD, MACP, from Harvard Medical School, has given a presentation at the ACP Internal ...
Antibody drug conjugates (ADCs) are advancing through clinical development with increasing complexity in both formulation and ...
Prescription Drug User Fee Act (PDUFA) target date of October 2026 ---- Submission supported by CESSA Phase 3 trial results demonstrating ...
Everyday Health on MSN
Common triptan mistakes: Why your acute migraine treatment might not be working
If triptans aren't alleviating your migraine attacks, learn what might be going wrong, from poor timing and low dosages to ...
Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant products to market, today announced the U.S.
TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first new FDA-approved treatment for fibromyalgia ...
Excipients contribute to more sustainable practices throughout the life cycle of a drug. Sustainability has become a core consideration in pharmaceutical manufacturing. It is driven by evolving global ...
Capsules are generally easier to swallow than tablets. Tablets have a long shelf life and are usually cheaper than capsules. Capsules and tablets serve the same purpose but vary in taste, composition, ...
The transdermal pathway serves as a significant route for achieving localized or systemic effects. Within this context, the stratum corneum is a crucial barrier limiting the permeation of many drugs.
Topical treatments for skin conditions offer significant benefits, yet understanding the rheological characteristics of semi-solid formulations is crucial, as they directly influence treatment ...
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 37 new drug formulations under the provisions of the Drugs (Prices Control) Order (DPCO), 2013, covering a wide ...
Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by this morning’s $1.9 billion biobucks deal. The U.S. drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results